Lineage Cell Therapeutics Cash Flow Statement (2010-2026) | LCTX

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Cash Flow Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Operating Activities
Net Income (Quarter)	-4.96M	-7.83M	-28.01M	-7.09M	-6.78M	-5.58M	-6.36M	-4.40M	-5.20M	-7.16M	-4.71M	-6.56M	-5.77M	-3.00M	-3.25M	-6.03M	-19.33M	-3.42M	16.17M	-7.19M
Depreciation and Depletion (Quarter)
Share-based Compensation (Quarter)	0.92M	1.14M		1.11M	1.24M	0.99M	0.96M	1.03M	1.28M	1.27M	1.06M	1.16M	1.27M	1.33M	1.31M	1.22M	1.24M	1.20M	1.10M	1.17M
Deferred Taxes (Quarter)	-0.17M	-1.01M						-1.80M	-0.00M
Gains from Sales and Divestitures (Quarter)	0.03M	0.05M	0.06M	0.02M	0.03M	0.03M	0.03M	0.08M	0.08M	0.08M	0.08M	0.07M	0.07M	0.07M	0.07M	0.07M	0.07M	0.07M	0.09M	0.07M
Gains from Investment Securities (Quarter)	5.12M	0.35M	-0.03M	5.30M	0.80M	0.24M	6.00M	0.01M	6.27M	25.44M	0.00M	0.34M	10.09M	0.50M		7.33M	12.74M	7.82M	0.00M	0.01M
Asset Writedowns and Impairment (Quarter)																	14.80M
Non-cash Items (Quarter)	6.39M	0.22M	6.39M	12.90M	10.90M	9.04M	1.36M	13.00M	1.37M	2.05M	1.05M	11.40M	10.50M	5.49M		0.01M	0.01M	10.15M	13.90M	13.25M
Cash from Operations (Quarter)	-5.42M	-4.85M	-5.87M	21.90M	-7.06M	-5.48M	-8.30M	-11.24M	-6.27M	-5.04M	-6.02M	-5.78M	-5.18M	-5.79M	-6.35M	-4.89M	-5.54M	-3.62M	-4.88M	-8.08M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter)	0.03M	0.03M	0.03M	0.03M	0.03M	0.05M	-0.01M	0.03M	0.03M	0.03M	0.03M	0.02M
Amortization of Deferred Charges (Quarter)
Depreciation & Amortization (CF) (Quarter)	0.16M	0.17M	0.16M	0.15M	0.15M	0.14M	0.14M	0.14M	0.14M	0.14M	0.14M	0.15M	0.14M	0.14M	0.15M	0.16M	0.17M	0.18M	0.19M	0.19M
Change in Working Capital
Change in Receivables (Quarter)	0.22M	-0.25M	0.75M	-50.32M	0.21M	-0.10M	-0.11M	-0.10M	0.24M	-0.01M	0.30M	-0.67M	0.16M	0.17M	0.23M	-0.42M	0.04M	-0.13M	0.83M	-0.15M
Change in Inventory (Quarter)
Change in Accured Expenses (Quarter)	0.08M	1.31M	21.29M	-18.91M	-0.33M	1.66M	-1.13M	-3.46M	-0.48M	0.48M	1.16M	-0.57M	-0.67M	-0.53M	0.10M	-0.10M	-0.35M	0.27M	2.46M	-1.71M
Other Working Capital Changes (Quarter)	-0.13M	0.82M	-0.71M	-4.87M	-4.14M	-2.59M	11.14M	-2.12M	-2.96M	5.02M	0.47M	-0.20M	-1.62M	0.93M	-6.79M	-1.28M	0.01M	-4.32M	5.55M	-0.99M
Investing Activities
Capital Expenditures (Quarter)	0.13M	0.05M	0.15M	0.05M	0.10M	0.29M	-0.40M	0.19M	0.26M	-0.44M	0.67M	0.04M	0.02M	0.14M	0.36M	0.10M	0.01M	-0.09M	0.50M	0.07M
Sales of Property, Plant and Equipment (Quarter)
Acquisitions (Quarter)
Divestments (Quarter)
Change in Acquisitions & Divestments (Quarter)								23.33M	24.33M	5.83M	9.83M			4.00M	-3.98M	2.00M				5.96M
Cash from Investing Activities (Quarter)	-0.12M	-0.07M	-0.15M	-0.05M	-0.10M	-40.91M	-5.10M	15.43M	19.16M	2.12M	9.74M	-0.04M	-8.79M	3.89M	2.63M	1.90M	-0.01M	-0.01M	-15.33M	-2.33M
Financing Activities
Other financing activities (Quarter)	0.92M	1.14M	0.92M	1.11M	1.24M	0.99M	0.01M	0.04M	1.28M	1.27M		0.02M				0.01M			0.00M	0.04M
Cash from Financing Activities (Quarter)	11.29M	3.72M	0.95M	0.51M	0.03M	0.96M	0.12M	0.00M	5.63M	0.81M	-0.01M	14.02M	0.10M	-0.00M	21.73M	5.04M	-0.31M	1.83M	20.38M	5.56M
Additional items
Exchange Rate Effect (Quarter)	0.04M	0.01M	0.01M	-0.04M	-0.12M	-0.63M	-0.08M	-0.10M	-0.09M	-0.34M	0.28M	-0.07M	-0.09M	0.04M	0.03M	-0.07M	0.29M	-0.00M	0.18M	-0.01M
Change in Cash (Quarter)	5.80M	-1.19M	-5.05M	22.33M	-7.25M	-46.06M	-13.36M	4.08M	18.43M	-2.45M	3.99M	8.13M	-13.95M	-1.86M	18.05M	1.99M	-5.57M	-1.80M	0.35M	-4.85M
Free Cash Flow (Quarter)	-5.54M	-4.90M	-6.02M	21.86M	-7.16M	-5.77M	-7.90M	-11.43M	-6.52M	-4.60M	-6.68M	-5.82M	-5.20M	-5.93M	-6.71M	-4.98M	-5.55M	-3.53M	-5.38M	-8.15M
Net Cash Flow (Quarter)	5.76M	-1.20M	-5.07M	22.37M	-7.13M	-45.43M	-13.28M	4.18M	18.52M	-2.11M	3.71M	8.20M	-13.86M	-1.90M	18.02M	2.06M	-5.86M	-1.79M	0.17M	-4.84M

Research Tools

Lineage Cell Therapeutics Cash Flow Statement (2010-2026) | LCTX

Create an account

Sign In

Reset Password